Dermata Therapeutics Inc (DRMA) Stock Price, Quote & News

Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 800 2543

Website: www.dermatarx.com

Address:

3525 Del Mar Heights Rd., Suite 332, San Diego, United States

Guestthatrader Mar. 13 at 6:40 PM

$DRMA webull still has it liquidated only

0 · Reply

Quantumup Mar. 12 at 12:08 PM

Citizens reiterated $SGMT Market Outperform; $35 and said, We continue to like SGMT's position in MASH, with the denifanstat/resmetirom combo targeting F4 MASH, which is the highest unmet need. $MDGL $IVA NVO LLY ALGS RHHBY ALGS VKTX $BHC $DRMA BFRI Here's what else Citizens had to say: https://x.com/Quantumup1/status/2032065360715784492?s=20

0 · Reply

SaltWaterChickens Mar. 11 at 7:57 PM

$DRMA $IPW good flipping

0 · Reply

Phazzatrades Mar. 10 at 5:45 PM

$DRMA

0 · Reply

wilo0915 Mar. 10 at 1:57 PM

$DRMA

0 · Reply

HolEKa1010 Mar. 9 at 6:56 PM

$DRMA

1 · Reply

Revempire Mar. 8 at 5:41 AM

$DRMA watching this one, maybe getting rdy for another run.

0 · Reply

FkGlobalists Mar. 6 at 3:01 PM

$DRMA

0 · Reply

David_M_ Mar. 5 at 2:32 PM

$DRMA https://finance.yahoo.com/news/dermata-opens-chapter-release-tome-140000715.html

1 · Reply

MrTicker Mar. 5 at 2:01 PM

$DRMA Dermata Opens a New Chapter with the Release of Tome Skincare ACCESS NEWSWIRE 8:00 AM ET 3/5/2026 The oldest new thing in skincare - - Dermata expects to launch its first product in the middle of 2026 - SAN DIEGO, CA / ACCESS Newswire / March 5, 2026 / Dermata

0 · Reply

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

Mar 5, 2026, 9:00 AM EST - 10 days ago

Dermata Opens a New Chapter with the Release of Tome Skincare

Jan 20, 2026, 8:05 AM EST - 7 weeks ago

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Dec 29, 2025, 4:05 PM EST - 2 months ago

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 24, 2025, 8:00 AM EST - 2 months ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 4, 2025, 8:00 AM EST - 3 months ago

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

Nov 14, 2025, 4:05 PM EST - 4 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Oct 2, 2025, 8:00 AM EDT - 5 months ago

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Sep 17, 2025, 1:00 AM EDT - 6 months ago

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 16, 2025, 8:35 AM EDT - 6 months ago

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Sep 10, 2025, 8:00 AM EDT - 6 months ago

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Aug 13, 2025, 5:00 PM EDT - 7 months ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 8, 2025, 8:00 AM EDT - 8 months ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

May 14, 2025, 9:00 AM EDT - 10 months ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 15, 2025, 8:30 AM EDT - 11 months ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Mar 27, 2025, 8:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 10:21 AM EDT - 1 year ago

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025, 9:57 AM EDT - 1 year ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 8:00 AM EDT - 1 year ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 17, 2025, 4:16 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 4, 2025, 8:03 AM EST - 1 year ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Feb 25, 2025, 7:58 AM EST - 1 year ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jan 29, 2025, 4:05 PM EST - 1 year ago

Dermata to Present on BioPub on January 31, 2025

Jan 28, 2025, 4:05 PM EST - 1 year ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 23, 2025, 4:15 PM EST - 1 year ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 1 year ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 21, 2025, 8:00 AM EST - 1 year ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dec 16, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 10, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 3, 2024, 9:00 AM EST - 1 year ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 13, 2024, 4:15 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 8:35 AM EST - 1 year ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Oct 8, 2024, 4:15 PM EDT - 1 year ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 1 year ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

May 17, 2024, 8:30 AM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 15, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Mar 27, 2024, 4:05 PM EDT - 2 years ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Feb 1, 2024, 9:00 AM EST - 2 years ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dec 20, 2023, 4:05 PM EST - 2 years ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Nov 16, 2023, 1:30 PM EST - 2 years ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 2 years ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Nov 9, 2023, 4:05 PM EST - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Aug 31, 2023, 9:00 AM EDT - 2 years ago

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Guestthatrader Mar. 13 at 6:40 PM

$DRMA webull still has it liquidated only

0 · Reply

Quantumup Mar. 12 at 12:08 PM

0 · Reply

SaltWaterChickens Mar. 11 at 7:57 PM

$DRMA $IPW good flipping

0 · Reply

Phazzatrades Mar. 10 at 5:45 PM

$DRMA

0 · Reply

wilo0915 Mar. 10 at 1:57 PM

$DRMA

0 · Reply

HolEKa1010 Mar. 9 at 6:56 PM

$DRMA

1 · Reply

Revempire Mar. 8 at 5:41 AM

$DRMA watching this one, maybe getting rdy for another run.

0 · Reply

FkGlobalists Mar. 6 at 3:01 PM

$DRMA

0 · Reply

David_M_ Mar. 5 at 2:32 PM

$DRMA https://finance.yahoo.com/news/dermata-opens-chapter-release-tome-140000715.html

1 · Reply

MrTicker Mar. 5 at 2:01 PM

0 · Reply

Guestthatrader Mar. 4 at 4:08 PM

$DRMA chart heating up positive news coming and earnings in should be released soon

0 · Reply

topstockalerts Mar. 3 at 9:06 PM

$DRMA primed for upside soon!!

1 · Reply

HolEKa1010 Mar. 2 at 8:03 PM

$DRMA omg so dead

1 · Reply

David_M_ Feb. 26 at 11:55 PM

$DRMA

1 · Reply

Guestthatrader Feb. 26 at 8:02 PM

$DRMA with volume nothing stopping it from running just need volume are buying pressure

0 · Reply

OfficialStocktwitsUser Feb. 26 at 6:27 PM

$DRMA RSI: 36.96, MACD: -0.2627 Vol: 0.42, MA20: 1.63, MA50: 1.99 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

1 · Reply

Guestthatrader Feb. 25 at 10:48 PM

$DRMA we got news but not the news we hoping for Board members resign Mary Fisher…. This could signal a acquisition she had the lowest value in the company her seat got bought out

0 · Reply

Guestthatrader Feb. 25 at 7:35 PM

$DRMA get in now if you can while prices is low to many positive catalyst in play for the squeeze some shorts are trap at the 1.24- 140 range if and when we get too the 2.50 range and break that it will run forever

0 · Reply

Guestthatrader Feb. 25 at 6:26 PM

$DRMA webull already stop taking buyers only can sell liquidity is thin

1 · Reply

Guestthatrader Feb. 25 at 6:23 PM

$DRMA don’t forget squeeze factor

0 · Reply

Guestthatrader Feb. 25 at 6:21 PM

$DRMA has all the key ingredients for a buyout big pharma may moved in

0 · Reply

Guestthatrader Feb. 25 at 6:18 PM

$DRMA

0 · Reply

Market Cap	3.37M
Revenue (ttm)	0.00
Net Income (ttm)	-12.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	98,200
Avg Vol	1,627,882
Day's Range	N/A - N/A
Shares Out	2.84M
Stochastic %K	33%
Beta	0.60
Analysts	Strong Sell
Price Target	$10.00